32 results about "Hydroxytryptophol" patented technology

A composition and method for treating Attention Deficit / Hyperactivity Disorder (ADHD) is provided which can be used both with and without ethical drugs now used to treat ADHD. The composition contains dimethylaminoethanol (DMAE), omega 3-fatty acids, betaine, oligomeric proanthocyanidins (OPC), folic acid, vitamins C, E, B12, B6, B5 and beta-carotene and minerals (calcium, magnesium, zinc and selenium). Ethical drugs such as amphetamines, methylphenidate HCl and pemoline are known to control ADHD, but each has significant side effects when used in their therapeutic dose. When combining the composition with such ethical drugs, the amount of the ethical drug can be lowered below a level which causes undesirable side effects which is an important feature. Preferred compositions contain one or more of lecithin, choline, 5-hydroxytryptophan, tyrosine, Reishi Extract, Kava Extract, Gingko, Ginseng and St. John's Wort.

The present invention relates to bifidobacterium breve CCFM1025, its fermented food and application thereof. Bifidobacterium breve CCFM1025 of the present invention can improve the depression-like behavior of depressed mice, increase the levels of 5-hydroxytryptophan, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice, and reduce the levels of 5-hydroxytryptophan in the serum of depressed mice. Corticosterone levels, increased serum 5-hydroxytryptamine levels in depressed mice, improved intestinal flora disturbance in depressed mice, decreased intestinal Veillonellaceae abundance, increased the abundance of Bifidobacteria and Mycoplasmaceae , increase the α-diversity of intestinal flora, reduce the occurrence of inflammatory bowel disease and obesity; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the level of 5-hydroxytryptophan in this cell Secretion, specifically providing precursors for the synthesis of 5-HT in the brain. It has broad application prospects.

The invention provides compounds, compositions, non-naturally occurring organisms, and methods useful for production of 5-hydroxytryptophan (5-HTP) in a microbial cell. A microbial system which includes at least one microbial cell, such as a bacterial cell or a yeast cell, is genetically engineered to express all or a portion of non-naturally occurring biosynthetic pathway that catalyzes the conversion of a simple carbon source, such as glucose, to 5-HTP. The invention can result in improved titers of 5-HTP and permits low-cost, large scale production. Methods of making and using the genetically engineered cells are also included in the invention.

This invention involves to Bacillus licheniformis JSC-69 for producing the 5-HTP, deposited as CGMCC NO: 13533; and a method for the producing 5-HTP using Bacillus licheniformis. Bacillus licheniformis JSC-69 said in this invention produces 5-HTP using tryptophan as the substrate, and the transformation efficiency is 95%˜100%.

The invention discloses a method for screening probiotics that realize antidepressant function through 5-hydroxytryptophan-related pathways based on cell level. Using RIN14B cells as a screening model, through the co-incubation of probiotics and cells, the secretion of 5-hydroxytryptophan in the cell supernatant and the mRNA level of tryptophan hydroxylase 1 in the cells were detected to determine the ability to pass 5-hydroxytryptophan Hydroxytryptophan probiotics exert antidepressant effects. The effective bacterial strain screened by the present invention can alleviate the depression-like behavior of depressed mice, improve the levels of neurotransmitters and neurotrophic factors in the brain, and reduce the hyperfunction of the hypothalamus-pituitary-adrenal axis caused by stress, and the results of cell model screening are consistent with those of animals. The experimental results have a significant correlation. The antidepressant potential of different bacterial strains can be measured in batches in a short time by using the invention, and a more rapid and efficient method is provided for the screening of probiotics with antidepressant function.

The present invention provides for novel combinations comprising an antihistamine with selected pharmaceutical and nutraceutical agents which alleviate some of the symptoms experienced by menopausal women, optionally combined further with a range of indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin. These mixtures may be enriched further with pharmaceutically acceptable calcium and magnesium salts as well as selected B vitamins. These combinations have utility in providing a medicament for improving health in mammals, especially for the improvement of menopausal symptoms as welt as sleep in women.